Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 31

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Clin Cases. Nov 6, 2023; 11(31): 7593-7609
Published online Nov 6, 2023. doi: 10.12998/wjcc.v11.i31.7593

Table 4 Kyoto Encyclopedia of Genes and Genomes pathway enrichment information

Pathway	Count	P value
Estrogen signaling pathway	11	1.09E-08
Thyroid hormone signaling pathway	10	5.77E-08
VEGF signaling pathway	7	5.6E-07
Toll-like receptor signaling pathway	8	1.92E-06
Prolactin signaling pathway	7	2.44E-06
FoxO signaling pathway	8	1.27E-05
PI3K-Akt signaling pathway	13	3.76E-05
HIF-1 signaling pathway	7	4.45E-05
Sphingolipid signaling pathway	7	5.48E-05
Neurotrophin signaling pathway	7	5.77E-05

VEGF: Vascular endothelial growth factor.

Citation: Yang Q, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. World J Clin Cases 2023; 11(31): 7593-7609
URL: https://www.wjgnet.com/2307-8960/full/v11/i31/7593.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i31.7593

Yang Q, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. World J Clin Cases 2023; 11(31): 7593-7609 [PMID: 38078145 DOI: 10.12998/wjcc.v11.i31.7593]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.